Technology area: Biotechnology & Pharmaceuticals
25 pending office actions • 13 art units • 22 examiners • 0 of 25 (0%) have an AI response strategy ready • 21 patents granted in the last 365 days
Fred Hutchinson Cancer Research Center has 26 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 23 examiners and 14 art units, showing broad examiner coverage with more substantial grouping by art unit.
ZHANG, KAIJIANG is the listed busiest examiner, with 3 pending matters. That examiner is a clear concentration point, although the majority of the portfolio remains assigned across other examiner relationships.
The art-unit distribution creates an opportunity to compare examination treatment among related biotechnology matters. Shared art-unit assignments may reveal recurring positions on claim scope or prior art, while the examiner spread counsels against treating any one response pattern as universally applicable.
Portfolio management should combine centralized tracking with matter-specific drafting. A common technical and disclosure framework can support consistency, but amendments and arguments should reflect the individual record before each examiner and the issues associated with each art unit.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 6 (24%) |
| §103 only | 1 (4%) |
| §102 only | 2 (8%) |
| §112 only | 6 (24%) |
| Double-patenting only | 1 (4%) |
| Double-patenting + other | 4 (16%) |
| Multi-statute (no §101) | 5 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHANG, KAIJIANG | 3 | 77.2% | +34.3% |
| PARISI, JESSICA DANIELLE | 2 | 75.0% | +33.5% |
| COHEN, MICHAEL P | 1 | 58.9% | +27.3% |
| YOO, SUN JAE | 1 | 71.2% | +0.3% |
| PYLA, EVELYN Y | 1 | 55.8% | +47.1% |
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.6% | +37.5% |
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.3% |
| REDDIG, PETER J | 1 | 58.0% | +40.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18661284 | Methods and Compositions for Inhibiting the Growth and/or proliferation of MYC-Driven Tumor Cells | YU, DAVID TUYANG | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18458108 | EPSTEIN BARR VIRUS VACCINES | WANG, RUIXUE | 49d overdue |
| 18500706 | COMBINATION THERAPIES FOR TREATMENT OF BCMA-RELATED CANCERS AND AUTOIMMUNE DISORDERS | REDDIG, PETER J | 5d |
| 17412105 | COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS | ZHANG, KAIJIANG | 65d |
| 18820648 | COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION | PYLA, EVELYN Y | — |
| 18707096 | T CELL IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCIES HAVING AN SF3B1 MUTATION | SZPERKA, MICHAEL EDWARD | — |
| 18639526 | METHODS OF TREATING SWI/SNF DEREGULATED CANCERS | ROZOF, TIMOTHY R | — |
| 18576216 | METHOD FOR ANALYZING THE ABILITY OF TARGET NUCLEIC ACID SEQUENCES TO IMPACT GENE EXPRESSION | PARISI, JESSICA DANIELLE | — |
| 18557406 | MOLECULAR SIGNATURES OF LONG-TERM COVID-19 AND TREATMENT THEREOF | CORNELIUS, CLAIRE ADRIENNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18500706 | COMBINATION THERAPIES FOR TREATMENT OF BCMA-RELATED CANCERS AND AUTOIMMUNE DISORDERS | REDDIG, PETER J | 5d |
| 17464341 | COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS | ZHANG, KAIJIANG | 65d |
| 17412105 | COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS | ZHANG, KAIJIANG | 65d |
| 19008094 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | COHEN, MICHAEL P | — |
| 17029756 | CELL POPULATION ANALYSIS USING SINGLE NUCLEOTIDE POLYMORPHISMS FROM SINGLE CELL TRANSCRIPTOMES | PARISI, JESSICA DANIELLE | — |
| 18820648 | COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION | PYLA, EVELYN Y | — |
| 18657687 | IMMUNOMODULATORY FUSION PROTEINS AND USES THEREOF | BRISTOL, LYNN ANNE | — |
| 18707096 | T CELL IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCIES HAVING AN SF3B1 MUTATION | SZPERKA, MICHAEL EDWARD | — |
| Art Unit | Apps |
|---|---|
| 1684 | 5 |
| 1641 | 4 |
| 1658 | 3 |
| 1672 | 2 |
| 1612 | 1 |
| 1621 | 1 |
| 1633 | 1 |
| 1625 | 1 |
| 1646 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19008094 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | COHEN, MICHAEL P | 1612 | §102§103§112DP | Non-Final OA | — | Pending | Jan 02, 2025 |
| 18797649 | COMPOSITIONS, KITS, AND METHODS TO INDUCE ACQUIRED CYTORESISTANCE USING STRESS PROTEIN INDUCERS | YOO, SUN JAE | 1621 | DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 17029756 | CELL POPULATION ANALYSIS USING SINGLE NUCLEOTIDE POLYMORPHISMS FROM SINGLE CELL TRANSCRIPTOMES | PARISI, JESSICA DANIELLE | 1684 | §103 | Final Rejection | — | Pending | Sep 23, 2020 |
| 18820648 | COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION | PYLA, EVELYN Y | 1633 | §103§112 | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18661284 | Methods and Compositions for Inhibiting the Growth and/or proliferation of MYC-Driven Tumor Cells | YU, DAVID TUYANG | — | §112Other | Non-Final OA | — | Pending | May 10, 2024 |
| 18657687 | IMMUNOMODULATORY FUSION PROTEINS AND USES THEREOF | BRISTOL, LYNN ANNE | — | §112 | Non-Final OA | — | Pending | May 07, 2024 |
| 18707096 | T CELL IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCIES HAVING AN SF3B1 MUTATION | SZPERKA, MICHAEL EDWARD | 1641 | §101§102§112 | Non-Final OA | — | Pending | May 02, 2024 |
| 18639526 | METHODS OF TREATING SWI/SNF DEREGULATED CANCERS | ROZOF, TIMOTHY R | 1625 | §102§112Other | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18576216 | METHOD FOR ANALYZING THE ABILITY OF TARGET NUCLEIC ACID SEQUENCES TO IMPACT GENE EXPRESSION | PARISI, JESSICA DANIELLE | 1684 | §101§103§112 | Non-Final OA | — | Pending | Jan 03, 2024 |
| 18500706 | COMBINATION THERAPIES FOR TREATMENT OF BCMA-RELATED CANCERS AND AUTOIMMUNE DISORDERS | REDDIG, PETER J | 1646 | §101§102§103§112Other | Non-Final OA | 5d | Pending | Nov 02, 2023 |
| 18288420 | Mesothelin-specific T cell Receptors and Methods of Using Same | JOHANSEN, PETER N. | 1658 | §112 | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18557406 | MOLECULAR SIGNATURES OF LONG-TERM COVID-19 AND TREATMENT THEREOF | CORNELIUS, CLAIRE ADRIENNE | 1672 | §101§103§112 | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18491703 | ANTI-FOLATE RECEPTOR CONJUGATE THERAPY FOR CANCER TREATMENT | HADDAD, MAHER M | 1641 | §102§103§112DP | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18458108 | EPSTEIN BARR VIRUS VACCINES | WANG, RUIXUE | 1672 | §103§112 | Non-Final OA | 49d overdue | Pending | Aug 29, 2023 |
| 18456339 | DELTA-LIKE NON-CANONICAL NOTCH LIGAND 1 ACTIVITY MODULATORS AND USES THEREOF | KOMATSU, LI N | 1658 | §112 | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18350637 | IGM-MULTIMERIZED SINGLE-DOMAIN ANTIBODIES THAT BIND ROR1 | PRIEST, JESSICA MARIE | 1642 | §112DP | Non-Final OA | — | Pending | Jul 11, 2023 |
| 18257814 | IMMUNOGENIC COMPOSITIONS | JUEDES, AMY E | 1644 | §101§102§112DP | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18251871 | THERAPEUTIC TARGETING OF MESOTHELIN IN ACUTE MYELOID LEUKEMIA WITH CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | HOWARD, ZACHARY C | 1674 | §103§112 | Final Rejection | — | Pending | May 04, 2023 |
| 18310649 | KSHV ONCOPROTEIN ANTIGENS AND EPITOPES FOR EXPANDING ANTIGEN-SPECIFIC T CELLS | ROONEY, NORA MAUREEN | 1641 | §112 | Final Rejection | 42d | Pending | May 02, 2023 |
| 18173485 | METHODS FOR ENHANCING ANTI-TUMOR ACTIVITY OF EXHAUSTED T CELLS | NGUYEN, QUANG | 1631 | §112 | Final Rejection | 2d overdue | Pending | Feb 23, 2023 |
| 17853716 | COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS | ZHANG, KAIJIANG | 1684 | §102Other | Non-Final OA | — | Pending | Jun 29, 2022 |
| 17464341 | COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS | ZHANG, KAIJIANG | 1684 | §102 | Non-Final OA | 65d | Pending | Sep 01, 2021 |
| 17412105 | COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS | ZHANG, KAIJIANG | 1684 | §101§102§112 | Non-Final OA | 65d | Pending | Aug 25, 2021 |
| 17312703 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FISCHER, JOSEPH | 1658 | §112DP | Final Rejection | — | Pending | Jun 10, 2021 |
| 17272117 | METHODS AND COMPOSITIONS FOR ADOPTIVE T CELL THERAPY INCORPORATING INDUCED NOTCH SIGNALING | DIBRINO, MARIANNE | 1641 | §103§112 | Non-Final OA | — | Pending | Feb 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFred Hutchinson Cancer Research Center has 25 pending office actions as of October 2026, spread across 13 art units and 22 examiners.
Kaijiang Zhang has the most, with 3 of Fred Hutchinson Cancer Research Center's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
